The Rationale to Combine Prexasertib With LY3300054 in Ovarian Cancer

Claire Manuszak, BS, research technician, Dana-Farber Cancer Institute, discusses the rationale to combine prexasertib (LY2606368) and LY3300054 in patients with high-grade serous ovarian cancer.
Website:
Twitter:
Facebook:
LinkedIn:

cancer,oncology,